SLC5A2 and heart failure: It was reported that there was no or very low expression of SGLT2 in the heart (Jiang et al., 2021), but SGLT2i improves heart failure and chronic kidney disease in patients with/without DM (Martinez et al., 2020; Wheeler et al., 2021), suggesting SGLT2-independent and glucose-lowering independent effects of SGLT2i.